Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr class="thead"><td align="left"></td><td align="center"><span style="width: 14.8375px;"><svg height="10.325" id="M3" style="vertical-align:-0.0pt" version="1.1" viewbox="0 0 14.8375 10.325" width="14.8375" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,10.325)">
<g transform="translate(72,-63.74)">
<text transform="matrix(1,0,0,-1,-71.95,63.79)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑁</tspan>
</text>
</g>
</g>
</svg></span></td><td align="center">Median</td><td align="center">Min</td><td align="center">Max</td></tr><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr><td align="left">PSA doubling time (months) pretreatment</td><td align="center">15</td><td align="center">4.7</td><td align="center">0.8</td><td align="center">9.9</td></tr><tr><td align="left" colspan="5"><hr/></td></tr><tr><td align="left">PSA doubling time (moths) on therapy</td><td align="center">15</td><td align="center">6.5</td><td align="center">0.8</td><td align="center">29.4</td></tr><tr class="table-tr"><td colspan="5"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

International Scholarly Research Notices

tab3

Table 3

Table 3: Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer 